Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products
Year: 2011
Type: letter
Abstract: together with the accompanying commentary from Dr Sesardic of NIBSC,[2] makes a new contribution to the data available for clinical botulinum toxin type A (BoNT-A) products. However, in addition to the comments about the various technical as-pects of the data provided by Dr Frevert, as de-scribed by Dr Sesardic,[2] one important and key factor about the BoNT-A products has not been mentioned. The units of each product are differ-ent, not interchangeable, and no fixed or estab-lished conversion ratio exists between them,[3-5] regardless of what clinical data are presented. This means that any data trying to represent the biochemical characteristics of the products in relation to their potency units, and then com-
Source: Drugs in R&D
Author: Andy Pickett
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,490
Funder: Ipsen
OpenAlex ID: W2045443530